Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)
Information source: Nycomed
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Common Cold
Intervention: xylometazoline hydrochloride and ipratropium bromide (ZyComb) (Drug)
Phase: N/A
Status: Completed
Sponsored by: Nycomed Official(s) and/or principal investigator(s): Nycomed Clinical Trial Operations, Study Chair, Affiliation: Headquaters
Summary
The objectives of the study are to obtain knowledge about the safety in use, the patients'
general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter
(OTC) setting.
Clinical Details
Official title: A Non-interventional, Non-controlled, Post-marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-life OTC Setting
Study design: Observational Model: Case-Only, Time Perspective: Prospective
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- For inclusion the patient must buy ZyComb® nasal spray with the intention to start
using it either the same or the next day.
Locations and Contacts
Additional Information
Starting date: December 2006
Last updated: May 4, 2012
|